Cambridge Research Biochemicals (CRB), a specialist in the custom production of polyclonal antibodies, is now expanding its antibody offering to include monoclonal antibody production via two new agreements with Babraham Bioscience Technologies (BBT) and Epitomics Inc.
CRB and Cambridge-based BBT have formed an alliance that will enable CRB to market custom monoclonal antibody projects (via mouse/rat hybridomas) from BBT. This will enable customers to take advantage of a shared, broader based expertise combining CRB capability in peptide synthesis for antigen use and the mAb production skills of BBT. This will considerably enhance CRB’s suite of offerings, as well as allowing BBT to open up its route to market.
In a further addition to its services, CRB has established a relationship with Epitomics that will enable CRB’s rabbit polyclonal antibody projects to be transferred to Epitomics’ rabbit monoclonal antibody (RabMAbsTM) projects. The resulting combined service will enable both commercial and non-commercial organisations to access the unique RabMAbs technology for research, diagnostics and therapeutics.
Emily Humphrys, CRB’s commercial director, said, ‘Our new alliances mean more options for our customers and access to unique technologies. We believe our partnerships can make a real difference to drug discovery.
‘CRB is continuing to grow and develop, and these latest joint ventures further strengthen our position in the industry.’